Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease
Document title: Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease
Journal: Annals of hepatology
Database: PERIÓDICA
System number: 000418435
ISSN: 1665-2681
Authors: 1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
Institutions: 1Pontificia Universidad Católica de Chile, Escuela de Medicina, Santiago de Chile. Chile
2Fundación Clínica Médica Sur, México, Distrito Federal. México
Year:
Season: Oct-Dic
Volumen: 10
Number: 4
Pages: 493-501
Country: México
Language: Inglés
Document type: Artículo
Approach: Analítico, descriptivo
English abstract The plasminogen activator inhibitor type-1 (PAI-1) has been implicated in the regulation of fibrinolysis and extracellular matrix components. The single base pair guanine insertion/deletion polymorphism (4G/5G) within the promoter region of the PAI-1 gene influences PAI-1 synthesis and may modulate hepatic fibrogenesis. Aim. To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients. Material and methods. Case-control study of 50 obese patients undergoing bariatric surgery and 71 non-obese subjects matched by age and sex. Anthropometric and biochemical measurements were performed, including PAI-1 serum levels. Genomic DNA was obtained to assess the presence of 4G/5G polymorphism. Results. BMI, insulinemia, triglycerides, HOMA-IR, hypertension and diabetes were significantly higher in obese patients compared to control subjects. PAI-1 serum levels observed in obese patients were significantly lower (10.63 ± 4.82) compared to controls (14.26 ± 11.4; p < 0.05). No differences were observed in the PAI-1 4G/5G promoter genotypes frequencies (p = 0.12). No differences were observed in PAI-1 plasma levels among obese patients with liver fibrosis (10.64 ± 4.35) compared to patients without liver fibrosis (10.61 ± 5.2; p = 0.985). PAI-1 4G/5G promoter genotypes frequencies were similar in patients with or without liver fibrosis associated to NASH (p = 0.6). Conclusions. Morbidly obese patients had significantly lower PAI-1 serum levels with similar PAI-1 4G/5G genotypes frequencies compared to non-obese subjects. The frequency of 4G/5G genotypes in Chilean Hispanic healthy subjects was similar to that described in other populations. No association was found between PAI-1 serum levels or 4G/5G genotype with liver fibrosis in obese patients
Disciplines: Medicina
Keyword: Gastroenterología,
Hígado graso no alcohólico,
Obesidad mórbida,
Inhibidor del activador de plasminógeno,
Polimorfismos de nucleótido único (SNPs),
Fibrosis hepática
Keyword: Gastroenterology,
Non alcoholic fatty liver,
Morbid obesity,
Plasminogen activator inhibitor,
Single nucleotide polymorphism (SNPs),
Liver fibrosis
Full text: Texto completo (Ver PDF)